Datar Cancer Genetics
- Home
- Companies
- Datar Cancer Genetics
- Products
- Easycheck - Model 360 - Screening ...
Easycheck - Model 360 -Screening Technology
EasyCheck 360 detects Circulating Tumor Cells (CTCs), which our research has shown to be present in most types of cancers. Our studies have shown that CTCs are detectable even in very early Stage 0 (in situ cancers) as well as Stage I and Stage II malignancies. CTCs are detected across all solid organ tumor types and subtypes, in men and women. CTCs do not exist in individuals without cancer. CTCs are undetectable in the blood of patients with non-cancerous (benign) tumors. CTCs, therefore, have high accuracy for the detection of cancer.
Most popular related searches
About EasyCheck 360®
EasyCheck 360® is an advanced non-invasive blood test which provides evidence of an underlying malignancy using a safe, simple and quick blood draw. EasyCheck 360® is designed to detect CTCs, which are cancer cells that escape from the tumor and enter the blood stream. EasyCheck 360® enriches these CTCs from the blood sample. These cells are characterized by ‘Immunocytochemistry’ (ICC). A positive CTC finding is indicative of the presence of an underlying cancer whereas, if CTCs are not detected, the individual is unlikely to have cancer*.
